Search research articles
Contact Us
Filters
Showing results (401-410 of 456) with videos related to
Page
of 46
Sort By:
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
Nature Medicine
|
January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Michael C Heinrich, Robin L Jones, Suzanne George, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
Amelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2024
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Mario Mandalà, Andrea Ferrari, Ines B Brecht, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
The New England Journal of Medicine
|
September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Lancet (London, England)
|
April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 12, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Mario Mandalà, Teresa Amaral, Piotr Rutkowski, et al.
Page
of 46
Search research articles
Search
Showing results (401-410 of 456) with videos related to
Sort By:
Page
of 46
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
Nature Medicine
|
January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Michael C Heinrich, Robin L Jones, Suzanne George, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
Amelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2024
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Mario Mandalà, Andrea Ferrari, Ines B Brecht, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
The New England Journal of Medicine
|
September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Lancet (London, England)
|
April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 12, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Mario Mandalà, Teresa Amaral, Piotr Rutkowski, et al.
Page
of 46